

RealRate

PHARMACEUTICAL 2021

Karuna Therapeutics Inc. Rank 23 of 402









PHARMACEUTICAL 2021



RealRate

Karuna Therapeutics Inc. Rank 23 of 402

The relative strengths and weaknesses of Karuna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karuna Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Karuna Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 241% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	344,599
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,853
Liabilities, Non-Current	1,841
Other Assets	2,577
Other Compr. Net Income	34
Other Expenses	43
Other Liabilities	0
Other Net Income	3,305
Other Revenues	0
Property and Equipment	449
Research and Development	43,408
Selling, General and Administrative Expense	28,408

Output Variable	Value in 1000 USD
Assets	347,625
Liabilities	8,694
Expenses	71,859
Revenues	0
Stockholders Equity	338,931
Net Income	-68,554
Comprehensive Net Income	-68,537
Economic Capital Ratio	289%

